552 related articles for article (PubMed ID: 33062720)
21. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.
Gasmi A; Peana M; Noor S; Lysiuk R; Menzel A; Gasmi Benahmed A; Bjørklund G
Appl Microbiol Biotechnol; 2021 Feb; 105(4):1333-1343. PubMed ID: 33515285
[TBL] [Abstract][Full Text] [Related]
22. The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
Martinez GP; Zabaleta ME; Di Giulio C; Charris JE; Mijares MR
Curr Pharm Des; 2020; 26(35):4467-4485. PubMed ID: 32634079
[TBL] [Abstract][Full Text] [Related]
23. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
[TBL] [Abstract][Full Text] [Related]
24. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.
Pereira BB
J Toxicol Environ Health B Crit Rev; 2020 May; 23(4):177-181. PubMed ID: 32281481
[TBL] [Abstract][Full Text] [Related]
25. Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.
Sun X; Ni Y; Zhang M
Emerg Microbes Infect; 2020 Dec; 9(1):830-832. PubMed ID: 32338155
[TBL] [Abstract][Full Text] [Related]
26. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
Mallhi TH; Ahmad A; Butt MH; Misbah S; Khan YH; Alotaibi NH
J Coll Physicians Surg Pak; 2020 Oct; 30(10):124-128. PubMed ID: 33115586
[TBL] [Abstract][Full Text] [Related]
27. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.
Cortegiani A; Ippolito M; Ingoglia G; Iozzo P; Giarratano A; Einav S
J Crit Care; 2020 Oct; 59():176-190. PubMed ID: 32683212
[TBL] [Abstract][Full Text] [Related]
28. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
29. Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists.
Mehta B; Moezinia CJ; Jannat-Khah D; Gibofsky A; Tornberg H; Pearce-Fisher D; Goodman SM; Salmon JE; Ibrahim S
J Clin Rheumatol; 2020 Sep; 26(6):224-228. PubMed ID: 32694358
[TBL] [Abstract][Full Text] [Related]
30. Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19.
Kiedrowski M; Kapala P; Kiedrowska M; Skoczynska A; Czerw A; Deptała A
Med Hypotheses; 2021 Jan; 146():110434. PubMed ID: 33277106
[TBL] [Abstract][Full Text] [Related]
31. Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.
Ruamviboonsuk P; Lai TYY; Chang A; Lai CC; Mieler WF; Lam DSC;
Asia Pac J Ophthalmol (Phila); 2020; 9(2):85-87. PubMed ID: 32349115
[TBL] [Abstract][Full Text] [Related]
32. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Nina PB; Dash AP
Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
[TBL] [Abstract][Full Text] [Related]
33. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection.
Klimke A; Hefner G; Will B; Voss U
Med Hypotheses; 2020 Sep; 142():109783. PubMed ID: 32402766
[TBL] [Abstract][Full Text] [Related]
34. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
Biguetti C; Marrelli MT; Brotto M
Rev Saude Publica; 2020; 54():68. PubMed ID: 32638884
[TBL] [Abstract][Full Text] [Related]
35. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
Zhao M
Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
[TBL] [Abstract][Full Text] [Related]
36. Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.
Gies V; Bekaddour N; Dieudonné Y; Guffroy A; Frenger Q; Gros F; Rodero MP; Herbeuval JP; Korganow AS
Front Immunol; 2020; 11():1409. PubMed ID: 32714335
[TBL] [Abstract][Full Text] [Related]
37. Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19.
Pillat MM; Krüger A; Guimarães LMF; Lameu C; de Souza EE; Wrenger C; Ulrich H
Cytometry A; 2020 Sep; 97(9):872-881. PubMed ID: 32686260
[TBL] [Abstract][Full Text] [Related]
38. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.
Malviya A
Indian Heart J; 2020; 72(2):131-132. PubMed ID: 32534688
[No Abstract] [Full Text] [Related]
39. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.
Singh AK; Singh A; Shaikh A; Singh R; Misra A
Diabetes Metab Syndr; 2020; 14(3):241-246. PubMed ID: 32247211
[TBL] [Abstract][Full Text] [Related]
40. Thoughts on COVID-19 and autoimmune diseases.
Askanase AD; Khalili L; Buyon JP
Lupus Sci Med; 2020; 7(1):e000396. PubMed ID: 32341791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
